United Therapeutics (NASDAQ:UTHR) Earns Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of United Therapeutics (NASDAQ:UTHR – Get Rating) in a research note released on Thursday. The brokerage issued a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $265.00 to $280.00 and gave the company an overweight rating in a research report on Thursday, February 23rd. Morgan Stanley dropped their target price on United Therapeutics from $330.00 to $320.00 and set an overweight rating on the stock in a research report on Thursday, February 23rd. LADENBURG THALM/SH SH dropped their target price on United Therapeutics from $295.00 to $285.00 in a research report on Thursday, February 23rd. Argus raised their price target on United Therapeutics from $250.00 to $300.00 and gave the company a buy rating in a research note on Wednesday, January 11th. Finally, UBS Group initiated coverage on United Therapeutics in a research note on Tuesday, December 6th. They issued a buy rating and a $320.00 price target for the company. Two analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $291.55.

United Therapeutics Trading Down 0.1 %

NASDAQ UTHR opened at $219.73 on Thursday. The firm has a market cap of $10.17 billion, a P/E ratio of 14.63, a P/E/G ratio of 1.63 and a beta of 0.62. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.85 and a quick ratio of 9.55. The stock’s 50-day moving average is $250.23 and its 200-day moving average is $246.69. United Therapeutics has a one year low of $173.21 and a one year high of $283.09.

United Therapeutics (NASDAQ:UTHR – Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $2.67 EPS for the quarter, missing analysts’ consensus estimates of $4.12 by ($1.45). The business had revenue of $491.50 million for the quarter, compared to analyst estimates of $519.20 million. United Therapeutics had a return on equity of 16.30% and a net margin of 37.56%. The company’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.35 EPS. Sell-side analysts anticipate that United Therapeutics will post 17.95 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,846,459.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $214.39, for a total transaction of $1,286,340.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,846,459.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Tuesday, December 20th. The shares were sold at an average price of $272.20, for a total value of $2,177,600.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $35,386. The disclosure for this sale can be found here. In the last three months, insiders sold 187,400 shares of company stock worth $48,069,013. 12.40% of the stock is owned by company insiders.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. DekaBank Deutsche Girozentrale raised its holdings in United Therapeutics by 0.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 26,081 shares of the biotechnology company’s stock valued at $5,362,000 after acquiring an additional 92 shares in the last quarter. Rockefeller Capital Management L.P. raised its holdings in United Therapeutics by 141.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 794 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 465 shares in the last quarter. Twin Tree Management LP raised its holdings in United Therapeutics by 273.0% in the 3rd quarter. Twin Tree Management LP now owns 4,457 shares of the biotechnology company’s stock valued at $933,000 after acquiring an additional 3,262 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in United Therapeutics by 41.3% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 9,287 shares of the biotechnology company’s stock valued at $1,945,000 after acquiring an additional 2,713 shares in the last quarter. Finally, Yousif Capital Management LLC raised its holdings in United Therapeutics by 1.3% in the 4th quarter. Yousif Capital Management LLC now owns 24,206 shares of the biotechnology company’s stock valued at $6,731,000 after acquiring an additional 310 shares in the last quarter. 95.63% of the stock is currently owned by institutional investors.

About United Therapeutics

(Get Rating)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.